ArticleLasers in medical science2025
Photobiomodulation as a therapeutic approach for attention-deficit/hyperactivity disorder in model rats.
Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Current treatment options for attention-deficit/hyperactivity disorder (ADHD) primarily involve pharmacological and behavioral interventions; however, concerns regarding side effects, long-term safety, and limited efficacy in certain populations highlight the need for alternative therapies. This study evaluates the effectiveness of photobiomodulation therapy (PBMT) in mitigating core symptoms of ADHD-specifically impulsivity and hyperactivity-in a spontaneously hypertensive rat (SHR) model, by assessing neuroinflammation, preservation of neuronal integrity, and brain connectivity. SHRs, a well-established ADHD animal model, were used to assess PBMT's effects. The experimental design included three groups: a normal control group (WKY), an ADHD model group receiving PBMT (SHR-PBMT), and an ADHD model group receiving sham treatment (SHR-Sham group). PBMT was administered daily for 25 s at a wavelength of 808 nm over 21 consecutive days. Behavioral assessments (open field test), diffusion tensor imaging (DTI), and immunohistochemical analysis were conducted to evaluate neuroinflammation, neuronal integrity, and myelination. SHR-PBMT reduced total track length by 28.4% (p = 0.003) and average speed by 22.7% (p = 0.012) compared to the SHR-Sham group. Fractional anisotropy in the prefrontal cortex increased by 15% (p < 0.05) following SHR-PBMT compared to the SHR-Sham group. The density of Iba-1 positive cells decreased by 35% ± 5% (p = 0.004), indicating significant suppression of microglial activation. Additionally, compared with the SHR-Sham group, the SHR-PBMT group preserved myelin integrity in ADHD-related brain regions, suggesting neuroprotective effects. The findings suggest that PBMT is an effective nonpharmacological intervention for ADHD, reducing impulsivity and hyperactivity while preserving neuronal structure and function. By mitigating neuroinflammation and improving neuronal connectivity, PBMT presents a promising therapeutic alternative to conventional ADHD treatments. Further studies are needed to explore its clinical applicability and long-term safety in human populations.
Indexed as
Identifiers
41068432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.